Genetic Mutation Analysis Market Report 2026

The genetic mutation analysis market size has grown rapidly in recent years. It will grow from $6.65 billion in 2025 to $7.43 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to limited access to advanced sequencing technologies, growing awareness of genetic disorders, increasing research in oncology and inherited diseases, adoption of pcr and microarray technologies, early development of bioinformatics tools.

The genetic mutation analysis market size is expected to see rapid growth in the next few years. It will grow to $11.47 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to advancements in crispr and ngs platforms, expansion of pharmacogenomics research, rising investments in genetic testing infrastructure, integration of ai-driven data interpretation tools, increasing collaborations between research institutes and biotech companies. Major trends in the forecast period include increasing adoption of next-generation sequencing and crispr technologies, rising demand for personalized medicine and targeted therapies, expansion of genetic testing services in clinical diagnostics, integration of bioinformatics and data analysis platforms, growth in research on rare genetic disorders and pharmacogenomics.

The rising prevalence of genetic disorders is expected to drive the growth of the genetic mutation analysis market in the coming years. Genetic disorders are diseases caused by abnormalities or mutations in an individual’s DNA, which may be inherited or occur spontaneously. The increase in these disorders is partly linked to advanced parental age, which raises the likelihood of genetic mutations during reproduction and consequently increases the risk of genetic disorders in offspring. Genetic mutation analysis identifies changes in genes that can cause or indicate the presence of genetic disorders, enabling early diagnosis, targeted treatments, and informed reproductive or lifestyle decisions. For example, according to the Cystic Fibrosis Trust in October 2024, the number of registered cystic fibrosis patients in the UK rose from 11,148 in 2022 to 11,318 in 2023, reflecting a 1.5% year-over-year increase in patient registrations. This growing prevalence of genetic disorders is therefore fueling the expansion of the genetic mutation analysis market.

Key companies in the genetic mutation analysis market are focusing on innovative solutions, such as tissue-based next-generation sequencing (NGS) tests, to enhance the precision of detecting actionable genetic alterations and guiding personalized treatment strategies. Tissue-based NGS tests are advanced diagnostics that analyze DNA or RNA from tissue samples to detect genetic mutations, alterations, or biomarkers associated with diseases such as cancer. For instance, in June 2024, Guardant Health Inc., a US-based oncology company, launched the Guardant360 TissueNext test, which expands the number of genes analyzed in tumor tissue samples to 498. These genes serve as cancer biomarkers, helping oncologists select the most effective targeted therapies for patients with advanced cancer. Additionally, the test features an improved operational workflow for faster turnaround times. Guardant360 TissueNext will be covered as a standalone service for Medicare fee-for-service patients with advanced solid tumors, based on coverage through Palmetto GBA under the Molecular Diagnostics Services program (MolDX).

In June 2023, Dotmatics Ltd., a US-based scientific informatics software company, acquired SoftGenetics for an undisclosed amount. This acquisition aims to enhance Dotmatics’ capabilities in genomics data analysis and bioinformatics by integrating SoftGenetics’ advanced genetic analysis tools, thereby strengthening its life sciences R&D platform and expanding its presence in the precision medicine and genetic research markets. SoftGenetics LLC, based in the US, specializes in bioinformatics software for mutation detection, sequencing, and forensic applications.

Major companies operating in the genetic mutation analysis market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., GenScript Biotech Corporation, Takara Bio Inc., 10x Genomics Inc., Oxford Nanopore Technologies Plc, Genomic Health Inc., Color Genomics Inc., Blueprint Medicines Corporation, GENEWIZ Inc., Pacific Biosciences of California Inc., Standard BioTools Inc., Personalis Inc., LGC Biosearch Technologies LLC, BGI Genomics Co. Ltd.

North America was the largest region in the genetic mutation analysis market in 2025. The regions covered in the genetic mutation analysis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genetic mutation analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the genetic mutation analysis market by increasing costs of imported sequencers, PCR machines, microarray instruments, and high-end software tools. Segments like hardware and advanced sequencing services are most affected, particularly in North America, Europe, and Asia-Pacific regions including China and India. This has led to higher operational costs and slowed deployment of advanced genetic testing solutions. On the positive side, tariffs have encouraged local manufacturing of instruments, development of cost-effective software, and investment in domestic bioinformatics capabilities.

The genetic mutation analysis market research report is one of a series of new reports that provides genetic mutation analysis market statistics, including genetic mutation analysis industry global market size, regional shares, competitors with a genetic mutation analysis market share, detailed genetic mutation analysis market segments, market trends and opportunities, and any further data you may need to thrive in the genetic mutation analysis industry. This genetic mutation analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genetic mutation analysis is the study and examination of changes in an organism’s DNA sequence that alter its genetic code. It focuses on identifying and characterizing variations such as base substitutions, insertions, deletions, or structural rearrangements within specific genes or genomic regions. This process aims to assess the nature and potential impact of these alterations, providing insights into the patterns, diversity, and implications of genetic changes.

The main components of genetic mutation analysis include hardware, software, and services. Hardware consists of laboratory equipment used to extract, amplify, and analyze genetic material for mutation detection. It employs various technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray, Sanger sequencing, and clustered regularly interspaced short palindromic repeats (CRISPR). Genetic mutation analysis is applied across multiple areas, such as oncology, cardiovascular diseases, neurological disorders, infectious diseases, genetic disorders, and pharmacogenomics, and serves key end users, including hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and diagnostic laboratories.

The genetic mutation analysis market consists of revenues earned by entities by providing services such as mutation validation, biomarker discovery, genome annotation, structural variation analysis, and epigenetic profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. The genetic mutation analysis market also includes sales of DNA extraction tools, mutation detection assays, sequencing panels, and genomic reference materials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.